The results of this study suggest that early inhibition of plasmin following severe injury by antifibrinolytics may provide further therapeutic benefits in patients with severe injuries by reducing SIRS and the risk of SIRS-related complications. This evidence concerns the gene PLG and systemic inflammatory response syndrome.